44 results about "CYP2C9*3" patented technology

A method of predicting the risk of a patient for developing phenytoin-induced adverse drug reactions (ADRs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reactions with eosinophilia and systemic symptoms (DRESS) is disclosed. Genetic polymorphisms of CYP2C genes (including rs1057910 (CYP2C9*3) and rs3758581 on CYP2C19), and HLA alleles (including HLA-B*1502, HLA-B*1301, and HLA-B*5101) can predict adverse reactions caused by phenytoin or fosphenytoin. Accordingly, the present invention provides a kit to assess the risk of a patient for developing adverse reactions in response to phenytoin-related drugs, which comprises the determination of the presence of a specific allele selected from the group consisting of rs1057910 (CYP2C9*3), rs3758581 on CYP2C19, HLA-B*1502, HLA-B*1301, and HLA-B*5101, wherein the presence of at least one allele is indicative of a risk for the adverse drug reactions.

The invention discloses a quick genotyping method for guiding Warfarin utilization starting dose and a kit and belongs to the gene detection technology in clinical detection technology in the biomedicine field. According to the quick genotyping method, the deoxyribonucleic acid (DNA) of a host cell gene group is extracted, and the gene types of CYP2C9*3(1061 A / C) and VKORCI (-1639 G / A) of a subject are measured. The CYP2C9 *3(1061 A / C) and VKORCI (-1639 G / A) genes have a nucleic acid sequence site shown as SEQ ID 1, wherein the site is one of the two most main sites associated with Warfarin metabolism. The invention provides the quick and accurate genotyping method and the associated kit. The method is quick and simple in operation, and low in cost, can be applied to prevention, auxiliary diagnosis and treatment on thrombotic associated diseases, and is conveniently popularized and used in basic medical institutions.

Disclosed is a primer set for amplifying a region in CYP2C9 gene that contains a detection target site having CYP2C9*3 therein by a gene amplification method, which enables to amplify the region specifically. A pair of primer set is used, which comprises a forward primer comprising a nucleotide sequence depicted in SEQ ID NO:4 and a reverse primer comprising a nucleotide sequence depicted in SEQ ID NO:17. The primer set enables to amplify a region containing a site having a polymorphism CYP2C9*3 occurring in CYP2C9 gene in a specific manner and with a high degree of efficiency.

The invention belongs to the technical field of biology and relates to a primer-probe combination and a kit for detecting associated genotyping of warfarin medication. The invention provides primers and probes for detecting associated genotyping of warfarin medication. The sequences of the primers are shown as SEQ ID NO.1-SEQ ID NO.6, and the sequences of the probes are shown as SEQ ID NO.7-SEQ ID NO.12. The primer-probe combination and the kit for detecting associated genotyping of warfarin medication have the advantages that development and application of the gene detection kit are guided through warfarin medication, typing of the three genes of CYP2C9*3, CYP4F2 and VKORC1 is facilitated and easily achieved, and noninvasive diagnosis is guaranteed to enable clinicians to master patient heredity conditions rapidly and accurately, decrease medical accident incidence caused by inappropriate medicine dose greatly, reduce medication side effect and lay the foundation for improvement on clinical treatment effect; since only about 2 hours is needed for detection of every sample, high detection speed is achieved.